1. Indinavir/Ritonavir 800/200 mg bid based regimen in multi-experienced HIV positive patients with extensive drug resistance. A.Vincenti1, L. Vatteroni2, F.Pacini1, A.Scasso1. 1)Hospital Lucca 2) University Pisa, Italy

2. An efficacious salvage regimen for multi- experienced patients failing PI has not been yet established

3. We evaluated a IDV/RTV 800/200mg b.i.d. regimen in combination with 2 NRTI with at least one of these efficacious toward the virus, in patients with virological multiple failure on a PI based regimen including IDV.

4. We enrolled 6 patients, that have been heavily pretreated and prior to initiating therapy, genotyping testing was performed revealing resistance both IDV and RTV. All patients were men, average age 46 yrs, (range 35-70). One patient had a vRNA very hight (6.8x10 6 cop/ml), CD4+30 cells/mmc; in the other 5 patients the median vRNA was 5.2log cop/ml, the median CD4+208 cells/mmc.

5. CD4+ c/mmc 0 w 12ws 48ws 1°pt 30 100 126 2°pt 105 *126 145 3°pt 121 245 294 4°pt 133 167 219 5°pt 470 788 6°pt 211 258 *the patient underwent a corneal transplantation for a cheratoconus with good results.

6. vRNA c/ml 0 w 12ws 48ws 1°pt 6.8x10 6 7.4x10 4 1.9x10 4 2°pt 3.9x10 5 *1.6x10 4 1.7x10 3 3°pt 2.5x10 5 <10 2 4°pt 1.3x10 4 <10 2 <10 2 5°pt 7.1x 10 4 1.5x10 2 6°pt 6.9x10 4 3.9x10 3 *the patient underwent a corneal transplantation for a cheratoconus with good results.

7. CONCLUSIONS *These data show that an enhanced PI regimen of IDV/RTV 800/200mg b.i.d. in combination with 2 NRTI was successfull in overcoming virological failure in heavily pretreated patients. *This regimen has a role as a salvage therapy also in patients that are resistant to these PI. *The regimen was well tolerated; no patient had clinical adverse events or nephrolitiasis.